Drug Population, Risk Should Receive Greater Attention In R&D – Wyeth VP
Executive Summary
Pharmaceutical R&D should focus more on targeting appropriate populations and risk assessment rather than immediate blockbuster potential, Wyeth VP-Project & Portfolio Management Richard Heaslip suggested
You may also be interested in...
Wyeth diet drug litigation
Wyeth increases Redux litigation reserve by $4.5 bil. ($2.6 bil. net of tax), bringing total fen/phen-related charges to $21.1 bil. Wyeth has paid $13.9 bil. in claims, leaving a balance of $7.2 bil. in reserve, as of Dec. 31. The charge assumes the so-called "Seventh Amendment" settlement will be accepted, although it still awaits final court approval. The Seventh Amendment would set aside $1.275 bil. to fund less serious cases (1"The Pink Sheet" Aug. 16, 2004, In Brief)...
Vioxx Liability Exposure May Exceed 5-Year Product Sales Of $12 Bil.
Merck's liability exposure from Vioxx could exceed total sales of the COX-2 inhibitor from its five years on the market
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011